[go: up one dir, main page]

WO2012119006A3 - Derivatives of pyrazole-substituted amino-heteroaryl compounds - Google Patents

Derivatives of pyrazole-substituted amino-heteroaryl compounds Download PDF

Info

Publication number
WO2012119006A3
WO2012119006A3 PCT/US2012/027341 US2012027341W WO2012119006A3 WO 2012119006 A3 WO2012119006 A3 WO 2012119006A3 US 2012027341 W US2012027341 W US 2012027341W WO 2012119006 A3 WO2012119006 A3 WO 2012119006A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted amino
pyrazole
heteroaryl compounds
derivatives
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/027341
Other languages
French (fr)
Other versions
WO2012119006A2 (en
Inventor
Craig Masse
Bhaumik PANDYA
Ian Robert Silverman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Priority to AU2012223281A priority Critical patent/AU2012223281A1/en
Priority to MX2013010067A priority patent/MX2013010067A/en
Priority to CA2829025A priority patent/CA2829025A1/en
Priority to EP20120751813 priority patent/EP2680843A4/en
Publication of WO2012119006A2 publication Critical patent/WO2012119006A2/en
Priority to US14/016,791 priority patent/US9145390B2/en
Anticipated expiration legal-status Critical
Publication of WO2012119006A3 publication Critical patent/WO2012119006A3/en
Priority to US14/840,952 priority patent/US9707218B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Fomula (I) and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).
PCT/US2012/027341 2011-03-03 2012-03-01 Derivatives of pyrazole-substituted amino-heteroaryl compounds Ceased WO2012119006A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2012223281A AU2012223281A1 (en) 2011-03-03 2012-03-01 Derivatives of pyrazole-substituted amino-heteroaryl compounds
MX2013010067A MX2013010067A (en) 2011-03-03 2012-03-01 Derivatives of pyrazole-substituted amino-heteroaryl compounds.
CA2829025A CA2829025A1 (en) 2011-03-03 2012-03-01 Derivatives of pyrazole-substituted amino-heteroaryl compounds
EP20120751813 EP2680843A4 (en) 2011-03-03 2012-03-01 Derivatives of pyrazole-substituted amino-heteroaryl compounds
US14/016,791 US9145390B2 (en) 2011-03-03 2013-09-03 Derivatives of pyrazole-substituted amino-heteroaryl compounds
US14/840,952 US9707218B2 (en) 2011-03-03 2015-08-31 Derivatives of pyrazole-substituted amino-heteroaryl compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448887P 2011-03-03 2011-03-03
US61/448,887 2011-03-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/016,791 Continuation US9145390B2 (en) 2011-03-03 2013-09-03 Derivatives of pyrazole-substituted amino-heteroaryl compounds

Publications (2)

Publication Number Publication Date
WO2012119006A2 WO2012119006A2 (en) 2012-09-07
WO2012119006A3 true WO2012119006A3 (en) 2014-04-17

Family

ID=46758504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/027341 Ceased WO2012119006A2 (en) 2011-03-03 2012-03-01 Derivatives of pyrazole-substituted amino-heteroaryl compounds

Country Status (5)

Country Link
EP (1) EP2680843A4 (en)
AU (1) AU2012223281A1 (en)
CA (1) CA2829025A1 (en)
MX (1) MX2013010067A (en)
WO (1) WO2012119006A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103304552B (en) * 2012-03-09 2016-12-28 广东东阳光药业有限公司 Substituted pyridine compounds and using method thereof and purposes
US20150299166A1 (en) 2012-12-20 2015-10-22 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
CN104650049B (en) * 2013-08-28 2018-06-08 广东东阳光药业有限公司 Substituted pyridine compounds and its application method and purposes
AU2018271110A1 (en) 2017-05-16 2019-12-05 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
CN114437058A (en) * 2020-10-30 2022-05-06 珠海宇繁生物科技有限责任公司 Deuterated HPK1 kinase inhibitor and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080021019A1 (en) * 2006-03-31 2008-01-24 Schering Corporation Kinase inhibitors
US7825137B2 (en) * 2005-12-05 2010-11-02 Pfizer Inc. Method of treating abnormal cell growth
US20100324061A1 (en) * 2004-08-26 2010-12-23 Agouron Pharmaceuticals, Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
CN101967140A (en) * 2010-09-14 2011-02-09 郑州泰基鸿诺药物科技有限公司 Deuterated crizotinib and its derivatives, preparation method and application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100324061A1 (en) * 2004-08-26 2010-12-23 Agouron Pharmaceuticals, Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US7825137B2 (en) * 2005-12-05 2010-11-02 Pfizer Inc. Method of treating abnormal cell growth
US20080021019A1 (en) * 2006-03-31 2008-01-24 Schering Corporation Kinase inhibitors
CN101967140A (en) * 2010-09-14 2011-02-09 郑州泰基鸿诺药物科技有限公司 Deuterated crizotinib and its derivatives, preparation method and application

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 2011-D34860, XP003031593 *
See also references of EP2680843A4 *

Also Published As

Publication number Publication date
EP2680843A2 (en) 2014-01-08
AU2012223281A1 (en) 2013-09-19
CA2829025A1 (en) 2012-09-07
EP2680843A4 (en) 2015-05-06
MX2013010067A (en) 2014-01-31
WO2012119006A2 (en) 2012-09-07

Similar Documents

Publication Publication Date Title
MX349159B (en) Deuterated derivatives of ivacaftor.
AU2012214029A8 (en) Rorgammat inhibitors
MX347988B (en) Phosphatidylinositol 3-kinase inhibitors.
MY178621A (en) Deuterated cftr potentiators
MY199894A (en) Prmt5 inhibitors and uses thereof
UA117830C2 (en) Bipyrazole derivatives as jak inhibitors
MX2015008187A (en) Deuterated alk inhibitors.
NZ708864A (en) Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
MX2011009796A (en) Inhibitors of pi3 kinase.
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2011011335A (en) Inhibitors of pi3 kinase and / or mtor.
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2014002683A (en) Benzonitrile derivatives as kinase inhibitors.
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
JO3115B1 (en) Pyridazinone Compounds and Their Use as DAAO Inhibitors
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
HK1205506A1 (en) Protein kinase inhibitors
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
MX363551B (en) Pyrazine kinase inhibitors.
WO2014016849A3 (en) Novel triazine compounds
WO2012119006A3 (en) Derivatives of pyrazole-substituted amino-heteroaryl compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12751813

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/010067

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2829025

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2012223281

Country of ref document: AU

Date of ref document: 20120301

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012751813

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012751813

Country of ref document: EP